$GILD News Selling in growth-stock leaders continues

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2013 at 9:59 PM

$GILD News

Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune 4:47 p.m. July 25, 2013 - Russ Britt
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Gilead profit up 8.6% on sales growth of HIV drugs 3:37 p.m. July 25, 2013 - MarketWatch.com
Gilead profit rises, sales beat forecast 3:19 p.m. July 25, 2013 - Russ Britt

'Mad Money' Lightning Round: Don't Sell Sirius 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:17 p.m. Nov. 8, 2013 - TheStreet.com
Gilead Vs. Challengers In The Hepatitis C Race 7:00 a.m. Nov. 7, 2013 - Seeking Alpha
Roche Pacing the Field in the Biotech Race 6:00 a.m. Nov. 6, 2013 - TheStreet.com
U.S. Launch of Actelion's Opsumit - Analyst Blog 4:30 p.m. Nov. 5, 2013 - Zacks.com
Ligand Pharmaceuticals On Pace For Annual Profit 4:25 p.m. Nov. 5, 2013 - Investors Business Daily
Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read 11:25 a.m. Nov. 5, 2013 - Wall St. Cheat Sheet
Gilead Sciences Inc Continues With Buy Recommendation 9:00 a.m. Nov. 5, 2013 - TheStreet.com
UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014 7:34 a.m. Nov. 5, 2013 - 247WallSt.com
Stock Splits Rekindle a Polarizing Debate 8:44 p.m. Nov. 4, 2013 - WSJ.com
Top-Performing Mutual Funds Like Facebook 5:01 p.m. Nov. 4, 2013 - Investors Business Daily
Bristol-Myers Seeks Japanese Approval - Analyst Blog 2:30 p.m. Nov. 4, 2013 - Zacks.com
Protect Your Investments Against a Bubble, Know What Makes a Bubble 10:28 a.m. Nov. 4, 2013 - TheStreet.com
Benzinga's Top #PreMarket Losers 7:37 a.m. Nov. 4, 2013 - benzinga.com
Invest In Gilead Sciences For Long-Term Hepatitis C Franchise 2:13 a.m. Nov. 4, 2013 - Seeking Alpha
Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV 4:15 p.m. Nov. 2, 2013 - benzinga.com
Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients 4:12 p.m. Nov. 2, 2013 - benzinga.com
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex 6:40 a.m. Nov. 2, 2013 - 247WallSt.com
Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1) 5:20 p.m. Nov. 1, 2013 - TheStreet.com
Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day 4:15 a.m. Oct. 31, 2013 - Zacks.com

S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver 9:31 a.m. Oct. 29, 2013 - PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 9:00 a.m. Oct. 28, 2013 - PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection 4:43 p.m. Oct. 25, 2013 - BusinessWire
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013 5:00 p.m. Oct. 22, 2013 - BusinessWire
Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics 8:00 a.m. Oct. 22, 2013 - PR Newswire
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer 9:05 a.m. Oct. 21, 2013 - PR Newswire
Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals 8:55 a.m. Oct. 21, 2013 - PR Newswire
Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy 3:10 a.m. Oct. 16, 2013 - BusinessWire
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection 7:00 a.m. Oct. 15, 2013 - Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beta Bionics Faces Securities Fraud Class Action Challenges

The Unexpected Slide of Beta Bionics So your wallet took a bruising with this Beta Bionics deal, eh? It’s another one of those wild tales from the stock jungle where everyone watching the NASDAQ:BBNX action got clipped when reality didn't match the company chest-thumping. Glancy Prongay Wolke & Rotter LLP just laid it out—ripping the Band-Aid off what Beta Bionics...

Atlantic Blvd Apartments: A Game-Changer for Housing

A Bold Move for Attainable Housing Amidst the hustle and bustle of Sterling, Virginia, a new player has hit the scene: Atlantic Blvd Apartments. A property designed solely for attainable housing, this development is a showcase of what can be accomplished when local government and private developers team up with a shared vision. It feels like a breath of fresh air in a...

Burns Harbor Bags $11.2M to Turbocharge Operations

Funding Boon for Burns Harbor It’s not every day you see a steady hand of federal money pouring into a port like Burns Harbor, and there’s an $11.2 million cherry on top from Uncle Sam to modernize this place. Yeah, you heard right—a cool eleven million to spruce up Indiana’s port operations, aimed straight at making Burns Harbor more nimble on the international...

Autodesk Ascends in Construction Software Arena

Autodesk Hits a High Note in Construction Management There's a new tune coming from Autodesk, and it's echoing across the construction industry. Tagged as a 'Leader' in the IDC MarketScape: Worldwide Construction Management Software 2026 Vendor Assessment, Autodesk, Inc. (NASDAQ:ADSK) isn't just playing along; it's setting the rhythm. The report, released on October 28,...

Scania's Q3 Results: A Resilient Yet Uneven Ride

Scania Steadies the Ship in Q3 with Robust Growth Sailing through a patchy global market, Swedish powerhouse Scania's latest quarterly figures reflect a mixed bag of results. Their performance in this third quarter of 2026 stood strong, despite some wobbles. The company showed resilience in sales and profitability, with numbers telling a tale that's a bit like a truck...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Step into Fear: Dead by Daylight in Moreno Valley

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

California Credit Union's Student Account Banks Big Goals

Financial Education for the Next Generation Here's the deal—credit unions aren't often the star of anyone's morning chat over a sloppy diner breakfast, but California Credit Union might just deserve a spotlight today. They've bagged the national Bank On certification for their Student Checking account. That means they’ve hit the jackpot in terms of meeting the...

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Kimberly-Clark Extends Kenvue Notes Exchange Deadline

Deadline Extended for Kenvue's Noteholders In the wild world of corporate finance, the only thing more unpredictable than the weather is a boardroom decision. Kimberly-Clark (NASDAQ: KMB) just threw one such curveball by extending the deadline on their exchange offers for Kenvue Notes to November 2, 2026. Seems like 5 p.m. New York time is the new witching hour for this...